Anemia, hemorrhage, and transfusion in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction

Area of Science:

• Cardiology
• Hematology
• Internal Medicine

Background:

• Antithrombotic and antiplatelet therapies have improved ischemic event rates in percutaneous coronary intervention (PCI), acute coronary syndromes (ACS), and ST-segment elevation myocardial infarction (STEMI).
• These advancements, however, are associated with a higher risk of hemorrhagic complications.
• Anemia and acute hemorrhage are frequent in these cardiovascular settings, correlating with increased morbidity and mortality.

Purpose of the Study:

• To review the pathophysiology of anemia in the context of cardiovascular interventions.
• To examine the impact of anemia and blood transfusions on patient outcomes in PCI, ACS, and STEMI.
• To discuss the risks associated with blood transfusion in anemic patients undergoing these procedures.

Main Methods:

• Literature review of studies on anemia, hemorrhage, and transfusion in cardiovascular interventions.
• Analysis of the pathophysiology linking anemia to adverse outcomes.
• Synthesis of data on the effects of blood transfusion on morbidity and mortality.

Main Results:

• Anemia and acute hemorrhage are prevalent in patients undergoing PCI, ACS, and STEMI.
• These conditions are independently associated with worse short-term and long-term prognoses.
• Blood transfusion, a common treatment, may paradoxically increase rather than decrease patient risk.

Conclusions:

• Anemia and hemorrhage represent significant challenges in managing patients with PCI, ACS, and STEMI.
• The role and risks of blood transfusion in these patients require careful consideration.
• Further research is needed to optimize management strategies for anemia and bleeding in cardiovascular care.